Aeon Biopharma Inc

Aeon Biopharma Inc exhibits a capital structure with a negative total equity of $27.95 million and a debt-to-equity ratio of -0.48, indicating a leveraged position with more liabilities than equity. The company's liquidity is assessed as medium, with a current ratio of 0.39, suggesting limited short-term liquidity to cover immediate obligations. Despite a negative net cash position after subtracting total debt, the company reported a free cash flow of $164.14 million, which may indicate strong cash generation from operations or asset sales.

In terms of profitability, Aeon Biopharma Inc reported an operating income of $153.47 million and a net income of $164.11 million, reflecting a strong performance in the most recent period. The return on assets (ROA) is 28.62%, which is significantly higher than the industry median, indicating efficient use of assets to generate profit. However, the return on equity (ROE) is negative at -5.87%, which is a concern as it suggests the company is not generating returns for its shareholders.

The company's revenue is not disclosed by segment or geography, but the negative total equity and high ROA suggest a concentration of risk in its core operations. There is no information available on geographic exposure or segment performance, which limits the ability to assess diversification and regional risk.

Looking ahead, the company's growth trajectory is not explicitly outlined in the provided data. However, the strong net income and free cash flow suggest potential for reinvestment or debt reduction. Analysts have provided a mean price target of $5.20, with a median of $5.20 and a high of $5.40, indicating a generally positive outlook despite the absence of strong-buy recommendations.

The risk assessment highlights a medium liquidity risk and a low dilution risk, with the key flag being the negative net cash position after subtracting total debt. There is no mention of recent events such as filings or transcripts that could provide additional context on the company's strategic direction or operational changes.

Operating income −137,4% YoY; Net income −1 883,7% YoY.

• ▍Operating income −137,4% YoY
• ▍Net income −1 883,7% YoY
• ▍Free cash flow −1 863,3% YoY

Operating income +37,9% YoY; Net income +26,5% YoY.

• ▍Operating income +37,9% YoY
• ▍Net income +26,5% YoY
• ▍Free cash flow +26,5% YoY

Operating income −102,8% YoY; Net income −104,0% YoY.

• ▍Operating income −102,8% YoY
• ▍Net income −104,0% YoY
• ▍Free cash flow −104,0% YoY

Operating income -$4.0M.

• ▍Operating income -$4.0M

Operating income $153.5M.

• ▍Operating income $153.5M

Operating income +121,0% YoY; Net income +110,9% YoY.

• ▍Operating income +121,0% YoY
• ▍Net income +110,9% YoY
• ▍Free cash flow +111,0% YoY